Drug Discovery & Pharmaceuticals

RSS

ELRIG announces Prof Rory Johnson and Dr Shalini Andersson as keynote speakers at Therapeutic Oligonucleotides 2025

ELRIG, a not-for-profit, volunteer-led organization for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D site in Gothenburg, Sweden from 14-15 May. Prof Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca will lead this year's event focused on 'drugging the undruggable'.

25 Mar 2025

Citrus remedy squeezes out dry mouth for cancer patients

A natural citrus oil from oranges, lemons, and limes is proving highly effective in relieving dry mouth, and when combined with a new lipid formulation, new research suggests it may be effective without significant side effects.

24 Mar 2025

New light-driven process could accelerate the discovery of new drugs

Researchers at Indiana University and Wuhan University in China have unveiled a groundbreaking chemical process that could streamline the development of pharmaceutical compounds, chemical building blocks that influence how drugs interact with the body.

22 Mar 2025

Anti-HIV active diterpenoids identified in Daphne pseudomezereum

A research group led by Professor Wei Li from the Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Toho University, in collaboration with the Duke University Medical Center in the United States, has discovered for the first time that Daphne pseudomezereum (commonly known as Onishibari) contains a substance inhibiting replication of human immunodeficiency virus (HIV).

21 Mar 2025

Registration Now Open for World Vaccine Congress Washington 2025: Leading Experts from Government, WHO, CEPI, and more to Speak

Register for the World Vaccine Congress 2025, the premier event for vaccine experts and leaders, driving innovations in public health and pandemic preparedness.

From World Vaccine Congress Washington 21 Mar 2025

Natural compounds identified as potential inhibitors of SARS-CoV-2 spike protein

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2.

20 Mar 2025

Scientists discover irreversible peptide inhibitors for undruggable cancer target

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it.

20 Mar 2025

Sapio Sciences makes AI-Native drug discovery seamless with NVIDIA BioNeMo

Sapio Sciences, the science-aware™ lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform.

From Sapio Sciences 20 Mar 2025

UCLA Health discovers drug that mimics stroke rehabilitation effects in mice

A new study by UCLA Health has discovered what researchers say is the first drug to fully reproduce the effects of physical stroke rehabilitation in model mice, following from human studies.

19 Mar 2025

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

To tackle the inequity in medication access, a societal issue especially in developing nations, a team of undergraduate student-researchers at the University of Ottawa has developed a new biomanufacturing platform called Phytogene.

18 Mar 2025

LGM Pharma invests $6 M in U.S. drug manufacturing capabilities for liquids, suspensions, semi-solids, and suppositories

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy.

13 Mar 2025

Shift Biosciences announces key appointments to advance rejuvenation therapeutics pipeline

Shift Biosciences, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the appointments of Jill Reckless, Ph.D, as Translation Advisor and Laurence Reid, Ph.D., as Non-Executive Director. In these roles, Jill and Laurence will guide Shift in building a robust product translation and business development strategy respectively, enabling the Company to capitalize on early momentum and progress its pipeline of novel rejuvenation therapeutics towards clinical development.

12 Mar 2025

New automated system revolutionizes drug evaluation in zebrafish

Preclinical drug evaluation, especially for cardiotoxicity, is a critical stage in the drug development process.

11 Mar 2025

British scientists unveil world-leading technology to speed up drug discovery

A new 3D bio-printer that produces human-like tissue holds the potential to revolutionize the discovery of new drugs for cancer, heart disease and arthritis.

10 Mar 2025

Vanderbilt researchers aim to use AI to develop antibody therapies for any target

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

8 Mar 2025

New drug VIP36 shows promise in treating pain without harmful side effects

A research team funded by the National Institutes of Health (NIH) has developed a medication that shows promise in treating acute and chronic pain.

5 Mar 2025

New chemical reaction enables precise functionalization of peptides and proteins

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables the precise functionalization of peptides and proteins.

28 Feb 2025

Microphysiological systems in drug discovery

NewsMedical speaks with CN Bio about the translatability between in vitro organ-on-a-chip (OOC) models, microphysiological systems, and their in vivo counterparts.

From CN Bio Innovations Ltd 26 Feb 2025

New antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumors

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors.

25 Feb 2025

Insilico Medicine reaches preclinical milestone in MASH drug discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH).